Alzheimer's drug Reminyl under review by European and Canadian officials; drugmaker's stock price falls on London market by Mike Adams the Health Ranger Officials in Europe and Canada have called into question a drug designed to treat mild cases of Alzheimer's disease. Clinical trials show that patients who took Reminyl were more likely to die of heart attacks and cancer. After news broke that the drug is under review, stock prices for the English company that developed the pill fell about 3.5 percent on the London exchange. American company Johnson & Johnson was a partner in the drug's development.This site is part of the Natural News Network 2008 All Rights Reserved. Privacy | Terms All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing International, LTD. is not responsible for content written by contributing authors. The information on this site is provided for educational and entertainment purposes only. It is not intended as a substitute for professional advice of any kind. Truth Publishing assumes no responsibility for the use or misuse of this material. Your use of this website indicates your agreement to these terms and those published here. All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners.
